International Markets and Danaher (DHR): A Deep Dive for Investors
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Danaher Q2 2025 Update
While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adjusted diluted net EPS guidance to a range of $7.70 to $7.80 vs previous range of $7.60 to $7.75. Compared to the past few years, Danaher's multiples have noticeably come down. However, it is hard for a stock to go up if revenue growth hovers around LSD level.
CVS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Here's Why Danaher (DHR) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Danaher Stock: Attractively Valued And Poised For Growth Acceleration
Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but a $150M cost-reduction plan and easing China headwinds should drive margin expansion from FY26 onward. The stock trades at a meaningful discount to historical valuation, offering compelling upside as earnings growth is set to reaccelerate post-FY25.
Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q2 2025 Earnings Conference Call July 22, 2025 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Matthew R. McGrew - CFO & Executive VP Rainer M.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Danaher (DHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Q2 Earnings and Revenues Top Estimates
Danaher (DHR) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.72 per share a year ago.
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.
Danaher (DHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Danaher (DHR) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
